• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Simvastatin as Adjunctive Therapy for Irritability in Autism

Simvastatin as Adjunctive Therapy for Irritability in Autism

June 21, 2018
Thomas Jordan, MD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Moazen-Zadeh E et al, J Child Adolesc Psychopharmacol 2018;28(1):82–89.

Disorders of lipid metabolism—specifically inefficient metabolism of lipids—have been implicated as part of the metabolic complexity in children with autism spectrum disorder. Research points to the neuroprotective effects of simvastatin over other statins, due to its greater ability to cross the blood-brain barrier. But does that neuroprotection translate to differences in behavior?

This 10-week randomized, double-blind, placebo-controlled trial compared simvastatin to placebo as adjunctive treatment to risperidone for irritability in children meeting criteria for DSM-IV-TR autistic disorder (AD).

All participants scored ≥ 12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale, and therefore met criteria for treatment of irritability with medications. The ABC-C scale rates children on 58 items arranged in 5 behavioral abnormality subscales. In total, 66 children ages 4–12 years completed the trial and were randomized to receive risperidone and either simvastatin or placebo. Risperidone target dose was 1 mg/day if < 20 kg and 2 mg/day if ≥ 20 kg. Simvastatin was started concurrently with risperidone and was dosed at 20 mg per day for children < 10 years old, and 40 mg per day if ≥ 10 years old. The ABC-C rating scale was assessed at baseline, for week 5, and week 10.

The primary outcome was change in the ABC-C irritability subscale, which showed a significant difference in favor of the simvastatin arm at week 10 (-3.45, p = 0.083). Secondary outcomes were the other four subscales, for which there was a significant improvement in the simvastatin group over placebo only in the hyperactivity/noncompliance subscale (-4.27, p = 0.001).

The other subscales that represent the core deficits of AD (lethargy/social withdrawal, stereotypic behavior, and inappropriate speech) showed no significant differences. There was also no significant difference in any adverse events between the groups. The more common side effects across both groups were increased appetite (25.8%), myalgia (13.6%), nausea (12.1%), and headache (12.1%).

CCPR’s take
The results of this study are promising, but it is only the first of its kind to evaluate simvastatin treatment in this clinical setting. Since long-term benefits or adverse effects have not been established, it’s too early to recommend this approach. As in studies of anti-inflammatory interventions, behavioral symptoms may be improved, but the core symptoms of autism remain unchanged.
Child Psychiatry
KEYWORDS autism-spectrum-disorder child_psychiatry research-update
Thomas Jordan, MD

Vyvanse for Sluggish Cognitive Tempo in ADHD

More from this author
www.thecarlatreport.com
Issue Date: July 16, 2018
SUBSCRIBE NOW
Table Of Contents
Note From the Editor-in-Chief
Prescribing Antipsychotics in Aggressive Children With ADHD
Including Parents in Autism Intervention
Acceptance and Commitment Therapy (ACT) for Children and Adolescents
Simvastatin as Adjunctive Therapy for Irritability in Autism
CME Post-Test - Autism in Children and Adolescents, CCPR, July/August 2018
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.